ADVERTISEMENT
Alkem Labs Q2 Review: Dolat Capital Upgrades EPS Estimate For FY26-27 Maintaining Add — Check New Target Price
Dolat Capital upgrades Alkem Labs' FY26E/FY27E EPS estimates by 3.5%/6.0%, assuming higher sales and Ebitda margin.
14 Nov 2025, 11:10 AM IST 
Save
As per IQVIA, in the Acute segment, Alkem became the number one company in IPM this quarter.
(Photo source: Company website)
Domestic business revenues grew 12.4% YoY in Q2 FY26 on a low base and outperformance in six therapies. As per IQVIA, Alkem Labs grew in line with the IPM at 6.4% in Q2 FY26.
